Martin Auster
Stock Analyst at Raymond James
(2.52)
# 2,383
Out of 5,012 analysts
51
Total ratings
55.26%
Success rate
11.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $13.95 | +150.90% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $459.58 | -7.74% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $54.70 | +119.38% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $29.74 | +253.06% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $9.24 | +181.39% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $5.52 | +2,073.91% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $17.92 | +1,574.11% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $27.31 | +112.38% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $456.84 | -57.10% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $1.83 | +5,255.19% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $162.32 | -63.04% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $39.50 | +64.56% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $23.12 | +215.74% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.43 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $57.92 | +34.67% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.09 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $9.43 | +355.99% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $46.95 | -27.58% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $20.44 | +2.74% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $29.87 | -46.43% | 1 | May 7, 2020 |
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $13.95
Upside: +150.90%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $459.58
Upside: -7.74%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $54.70
Upside: +119.38%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $29.74
Upside: +253.06%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $9.24
Upside: +181.39%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.52
Upside: +2,073.91%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $17.92
Upside: +1,574.11%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $27.31
Upside: +112.38%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $456.84
Upside: -57.10%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.83
Upside: +5,255.19%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $162.32
Upside: -63.04%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $39.50
Upside: +64.56%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $23.12
Upside: +215.74%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.43
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $57.92
Upside: +34.67%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.09
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $9.43
Upside: +355.99%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $46.95
Upside: -27.58%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $20.44
Upside: +2.74%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $29.87
Upside: -46.43%